We’re developing faster, more effective tools to help our partners solve the biggest healthcare challenges in neurodegeneration and psychiatry.
We have developed the world’s most advanced, at-home, medical grade, flexible data collection and analytics platform to solve some of the biggest challenges in monitoring functional brain health and brain disorders. Brain disorders are a growing global challenge, but drug discovery and management of these CNS diseases are hampered by late diagnosis, poor stratification and difficulty in monitoring patients.
Cumulus Neuroscience’s platform is designed to be the gold-standard for CNS assessments, providing the critical data and insight needed for faster, more robust and cost-effective clinical trials that improve the delivery of new therapies to patients. It allows frequent at-home use, combining neurophysiological monitoring (EEG) time-linked with a range of assessment tools.
Cumulus was formed in collaboration with leading global pharmaceutical companies to meet the industry’s complex clinical trial needs. We are the only company with a ‘paid-in’ pharma advisory consortium, and several of these companies have studies underway using Cumulus’ platform.
We assess cognition with patients in their home setting using tablet-based, real-world translations of lab-based tasks. These have been designed for repeated longitudinal assessment of working memory, episodic memory, executive function, decision making, and other cognitive functions. We continually look to include more tests as they become relevant and compatible with home use.
We have developed a first-in-class, home-usable EEG headset that can track neuronal integrity, network connectivity and compensation strategies, synchronised with tablet-based functional assessments of behavioural domains – all in a secure cloud-based storage and machine learning architecture that allows us to safely analyse composite behavioural, physiological and functional data.
Our platform integrates P1vital Products’ Facial Expression Recognition Task (FERT) to assess emotional bias. P1vital is a leader in computerised behavioural testing in clinical trials for mood and other psychiatric domains. The P1vital FERT is a well validated objective assessment of how someone processes emotional information and can provide an indication of current mood. The FERT is used widely in both clinical trials and healthcare settings to provide an early detection of treatment response.
We leverage Winterlight Labs’ state of the art algorithms and database to assess word choice, grammar and the acoustic properties of speech. Winterlight Labs has developed a proprietary language-based diagnostic system that analyses natural speech to detect and monitor dementias including Alzheimer’s, aphasia, and various other cognitive conditions.
Our platform integrates easy-to-use, clinically-validated sleep assessment tools that enable remote measurement of sleep quality metrics and sleep staging.
Powerful proprietary machine learning-based methods allow us to automatically evaluate the rich multi-dimensional real-world data we collect and rapidly generate meaningful insights. This allows detection of small but highly relevant changes in patients and provides the best, most rapid and cost-effective assessment of treatment outcomes, maximizing the chances of trial success.
Venture partner SV Health Investors, co-founder of DDF companies Loqus23 and AstronauTX. 25 years’ experience in Pharma at Merck and Pfizer. Trustee Alzheimer’s Research UK, Chair of UK’s BioIndustry Association.
Head of LifeArc Ventures, responsible for portfolio of direct and LP investments across the life sciences sector. Board member of the UK Biotechnology Industry Association and director of a number of venture-backed companies.
CFO (UK) SV Health Investors, heading up European finance operations, providing UK team with investment support in the six diversified SVLS Funds, the Dementia Discovery Fund, and SV7 Impact Medicine Fund.
Prof. Ritchie is Professor of the Psychiatry of Ageing at the University of Edinburgh and Director of Brain Health Scotland. He is a leading authority on clinical trials in Alzheimer’s disease and leads two major cohort studies: the European Prevention of Alzheimer’s Dementia (EPAD) and PREVENT Dementia Programmes.
Dr. Hughes is former Vice President and Head of CNS Growth Strategy at IQVIA. She is an expert in neurocognitive assessment and design of appropriate studies to assess Alzheimer’s Disease and neurocognitive dysfunction.
Prof. Jaeger is President of CognitionMetrics, LLC and Prof. Clinical Psychiatry & Behavioural Sciences at Albert Einstein College of Medicine. Former positions include Vice President for Clinical Trials at Cogstate and Director Clinical Development at AstraZeneca Pharmaceuticals.
Prof. McDade specialises in cognitive and behavioural neurology. He is Associate Professor of Neurology at Washington University School of Medicine in St Louis. and Associate Director of the DIAN Trials Unit.
Gerry Reilly is Technologist in Residence at Health Data Research UK, the national institute for health data in the UK, where he is senior advisor on long-term trends in technology and computer science, imaging and privacy enhancing technologies. He is also a member of the Executive Leadership Team for the International COVID-19 Data Alliance.
Mr. Mather is an Executive Director in Pfizer’s Early Clinical Development organization and has more than 20 years of experience in pharmaceutical research. He leads Pfizer’s Advanced Science group, validating technology platforms and qualifying novel digital endpoints.
Cumulus Neuroscience is the only company supported by a paid-in advisory group of ten of the world's leading pharmaceutical companies. Five companies (Biogen, GSK, Pfizer, Lilly, and Takeda) are limited partners in the Dementia Discovery Fund, the lead investor in Cumulus Neuroscience, joined by Bristol Myers Squibb, Boehringer Ingelheim, Merck, Roche and Janssen.
Cumulus is backed by experienced life science and technology investors, as well as UK and EU backed innovation agencies.